Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxalta Brings Japan Suit Against Chugai Hemophilia Antibody

This article was originally published in PharmAsia News

Executive Summary

Roche group member Chugai is facing legal action in Japan from Baxalta over claimed infringement of a hemophilia drug patent.

You may also be interested in...



Shire Builds Confidence In $20bn Revenue Target

Shire's first investor R&D day after its major acquisition of Baxalta earlier this year saw management keen to "bring confidence to the $20bn revenue target figure that we have stated," said CEO Flemming Ornskov. Shire's hemophilia focus, in particular, is facing some scrutiny.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.

Takeda Sees Mainstays Tiding It Over Upcoming Expiries

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Topics

Related Companies

UsernamePublicRestriction

Register

SC089490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel